Disposition of naltrexone after intravenous bolus administration in wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats

Neuropsychobiology

Volumn 58, Issue 2, 2008, Pages 81-90

  Akala, Emmanuel O ^a   Wang, Hu ^a   Adedoyin, Adedayo ^b  

^a HOWARD UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

High alcohol drinking rat; Low alcohol drinking rat; Naltrexone; Pharmacokinetics profile

Indexed keywords

ALCOHOL; NALOXONE; NALTREXONE;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; JUGULAR VEIN; LIVER BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS; WISTAR RAT;

ALCOHOL DRINKING; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAVENOUS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 52849140014     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159776     Document Type: Article

References (35)

1. Weiner RM, O'Brien CP: Naltrexone in the treatment of alcoholism. Annu Rev Med 1997;48:477-487.
2. Fuller RK, Hiller-Sturmhofel S: Alcoholism treatment in the United States: an overview. Alcohol Res Health 1999;23:69-77.
3. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992;49:881-887.
4. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP: A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol dependent patients. Neuropsychopharmacology 2003;28:1546-1552.
5. O'Brien CP: Research advances in the understanding and treatment of addiction. Am J Addiction 2003;12:S36-S37.
6. Volpicelli JR, Rhines KC, Rhines JS: Naltrexone and alcohol dependence. Arch Gen Psychiatry 1997;54:737-742.
7. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R: A multicenter, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593.
8. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA: Veterans Affairs naltrexone cooperative study G (2001): naltrexone in the treatment of alcohol dependence. New Engl J Med 2001;345:1734-1739.
9. Kranzler H, Modesto-Lowe V, Van Kirk J: Naltrexone versus nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 2000;22:493-503.
10. Johnson DAW: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 1984;5:13-21.
11. Wall ME, Brine DR, Perez-Reyes M: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Meta Dispos 1981;9:370-375.
12. Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile A: Viitrex®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for one month in rats. Neuropsychopharmacology 2003;28:1973-1982.
13. Medications for treating alcohol dependence; in Leonard B (ed): Helping Patients Who Drink Too Much: A Clinician's Guide. Derby, Diane, 2005, p 16.
14. Yin W, Akala E, Taylor R: Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. Int J Pharm 2002:244:9-19.
15. McBride WJ, Li TK: Animal models of alcoholism: neurobiology of high alcohol-drinking behavior on rodents. Crit Rev Neurobiol 1998;12:339-369.
16. Murphy JM, Stewart RB, Bell RL, Badia-Elder NE, Carr LG, McBride WJ, Lumeng L, Li TK: Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behav Genet 2002;32:363-388.
17. Malspeis L, Bathala MS, Ludden TM, Bhat HB, Frank SG, Sokoloski TD, Morrisson BE, Reuning RH: Metabolic reduction of naltrexone. I. Synthesis, separation and characterization of naloxone and naltrexone reduction products and quantitative assay of urine and bile following administration of naltrexone, alpha-naltrexol, or beta-naltrexol. Res Commun Chem Pathol Pharmacol 1975;12:43-65.
18. Reuning RH, Batra VK, Ludden TM, Hao MY, Morrison BE, McCarthy DA, Harrigan SE, Ashcraft SB, Sams RA, Bathala MS, Staubus AE, Malspeis L: Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. J Pharm Sci 1979;68:411-416.
19. Garrett ER, el-Koussi A el-D: Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. J Pharm Sci 1985;74:50-56.
20. Reuning RH, Liao SHT, Staubus AE, Ashcraft SB, Down DA, Harrigan SE, Wiley JN, Wise DL: Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system. J Pharmacokinet Biopharm 1983;11:369-387.
21. Rodd ZA, Bell RL, McKinze DL, Webster AA, Murphy JM, Lumeng L: Low-dose stimulatory effect of ethanol during adolescence in rat lines selectively bred for high alcohol preference. Alcohol Clin Exp Res 2004;28:535-543.
22. Stewart RB, Murphy JM, Lumeng L, Li TK: Intake of saccharin solution in selectively-bred high and low alcohol drinking (HAD and LAD) lines of rats and in the F2 progeny of HAD and LAD rat crosses. Alcohol Clin Exp Res 1998;22:A55.
23. Badia-Elder NE, Stewart RB, Powrozek TA, Murphy JM, Li TK: Effects of Neuropeptide Y (NPY) on ethanol intake and anxiety in high and low alcohol drinking (HAD1/LAD1) rats. Alcohol Clin Exp Res 2000;24:A82.
24. O'Connor EF, Cheng SW, North WG: Simultaneous extraction and chromatographic analysis of morphine, dilaudid, naltrexone and naloxone in biological fluids by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1989;491:240-247.
25. Reuning RH, Ashcraft SB, Wiley JN, Morrison BE: Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys. Drug Metab Dispos 1989;17:583-589.
26. Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL: In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Rel 2005;102:509-520.
27. Berkowitz BA, Spector S, Lee CH: Mechanism of narcotic antagonist and narcotic antagonist analgesic action;in Ford DH, Clouet DH (eds): Tissues Responses to Addictive Drugs. Spectrum Publications, Jamaica, NY, 1976, pp. 139-153.
28. Pace NL, Parrish RG, Lieberman MM, Wong KC, Blatnick RA: Pharmacokinetics of naloxone and naltrexone in the dog. J Pharmacol Exp Ther 1979;208:254-256.
29. Lieber CS: Medical and nutritional complications of alcoholism: mechanism and management. New York, Plenum Press, 1992, 165-183.
30. Rodd ZA, Bell RL, Sable HJK, Murphy JM, McBride WJ: Recent advances in animal models of alcohol craving and relapse. Pharmacol Biochem Behav 2004;79:439-450.
31. Hoffman PL, Miles M, Edenberg HJ, Somer W, Tabakoff B, Wehner JM, Lewohi J: Gene expression in brain: a window on ethanol dependence, neuroadaptation, and preference. Alcohol Clin Exp Res 2003;27:155-168.
32. Dayton HE, Inturrissi CE: Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Drug Metab Dispos 1976;4:474.
33. Crabtree BL: Review of naltrexone, a long-acting opiated antagonist. Clin Pharm 1976;3:273-280.
34. Vereb K, Volavka J, Mule SJ, Resnick RB: Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-328.
35. Ludden TM, Bathala MS, Malspeis L, Drum MA, Reuning RH: Elimination of radioactivity following administration of [15, 16 3H] naltrexone to rats and guinea pigs. Drug Met Dispos 1978;6:321-328.